Pharmaceutical Technology
JULY 17, 2024
In January, the US House Select Committee on the Strategic Competition between the US and the Chinese Communist Party introduced the Biosecure Act.
Bio Pharma Dive
JULY 17, 2024
Treatment led to "clinically meaningful" weight loss over four weeks, but longer studies will be needed to compare it to Wegovy and Zepbound.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Pharmaceutical Technology
JULY 17, 2024
The US FDA has issued a complete response letter (CRL) to Orexo regarding its NDA for OX124 to counteract opioid overdoses.
Bio Pharma Dive
JULY 17, 2024
Jefferies analyst Andrew Tsai views growing sales for J&J’s depression treatment as evidence that psychedelics like it can be commercially viable.
Speaker: Simran Kaur, Co-founder & CEO at Tattva Health Inc.
AI is transforming clinical trials—accelerating drug discovery, optimizing patient recruitment, and improving data analysis. But its impact goes far beyond research. As AI-driven innovation reshapes the clinical trial process, it’s also influencing broader healthcare trends, from personalized medicine to patient outcomes. Join this new webinar featuring Simran Kaur for an insightful discussion on what all of this means for the future of healthcare!
AuroBlog - Aurous Healthcare Clinical Trials blog
JULY 17, 2024
Can you pass me the whatchamacallit? It’s right over there next to the thingamajig. Many of us will experience “lethologica”, or difficulty finding words, in everyday life. And it usually becomes more prominent with age.
Bio Pharma Dive
JULY 17, 2024
Merdad Parsey joined Gilead as its chief medical officer in 2019 and has helped lead the company’s expansion into oncology, with mixed success.
Clinical Research Informer brings together the best content for clinical researchers from the widest variety of industry thought leaders.
Bio Pharma Dive
JULY 17, 2024
Caribou is slashing its workforce by 12%. Elsewhere, a CDMO is investing in GLP-1 drug demand and Beam’s CFO is returning to J.P. Morgan.
Pharmaceutical Technology
JULY 17, 2024
Upperton Pharma has received the UK Medicines and Healthcare products Regulatory Agency (MHRA) approval for its facility in Nottingham.
Bio Pharma Dive
JULY 17, 2024
The Series A round was led by healthcare investor The Column Group, which made the 17-year-old biotechnology company private earlier this year.
Pharmaceutical Technology
JULY 17, 2024
As US China trade relations are set to be impacted by the BIOSECURE Act, pharma companies exploring CDMOs outside China may need to contend with increased drug development and manufacturing costs.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
Bio Pharma Dive
JULY 17, 2024
Diagnostics is the largest industry represented in the data, with more than 5,000 affected positions, according to an analysis by MedTech Dive.
Pharma Times
JULY 17, 2024
The most globally prevalent cancers include breast, lung, bowel and prostate cancers
Rethinking Clinical Trials
JULY 17, 2024
Dr. Brendan Everett and Dr. Deborah Wexler In this Friday’s PCT Grand Rounds, Brendan Everett and Deborah Wexler of Harvard Medical School will present “Lessons From PRECIDENTD: A Pragmatic Comparative Effectiveness Trial.” The Grand Rounds session will be held on Friday, July 19, 2024, at 1:00 pm eastern. The PRECIDENTD study (Prevention of Cardiovascular and Diabetic Kidney Disease in Type 2 Diabetes) is comparing SGLT2 inhibitors and a GLP-1 receptor agonist to treat type 2
Pharmaceutical Technology
JULY 17, 2024
Approval of tabelecleucel would mark the first available therapy for the treatment of EBV+PTLD in the US.
pharmaphorum
JULY 17, 2024
Roche has reported early-stage clinical data with an oral GLP-1 agonist acquired as part of its $3.
Pharmaceutical Technology
JULY 17, 2024
The new funding is set to fund the expansion of the company’s Phase IIb studies into visugromab in combination with checkpoint inhibitors.
pharmaphorum
JULY 17, 2024
Get insights into Dr James Burt's leadership as CEO of Pharmanovia through a 12-question interview that covers his background, achievements, and vision for the company.
Pharmaceutical Technology
JULY 17, 2024
AbbVie has maintained a strong position within the immunology space for the past few years, largely due to the success of its antitumour necrosis factor (TNF) agent, Humira (adalimumab).
Advertisement
White paper that delves into the complex topic of Decentralized Clinical Trials and how to master them within the confines of FDA Regulations
pharmaphorum
JULY 17, 2024
Discover how artificial intelligence is revolutionising drug development and compliance in the pharmaceutical industry with these four impactful ways.
Pharmaceutical Technology
JULY 17, 2024
Biomanufacturers must tread carefully when seeking the optimum solution for their drug product's commercial supply chain.
FDA Law Blog
JULY 17, 2024
By Sarah Wicks & James E. Valentine & Frank J. Sasinowski — On July 17, 2024, FDA announced the establishment of a Rare Disease Innovation Hub (the “Hub”) to enhance and improve outcomes for patients with rare diseases and conditions by focusing on rare disease drug and biological product development across the Agency’s Center for Drug Evaluation and Research (“CDER”) and Center for Biologics Evaluation and Research (“CBER”).
Pharmaceutical Technology
JULY 17, 2024
Gene therapy trials can often be held back by cost and complexity. New database software is helping optimise the process.
pharmaphorum
JULY 17, 2024
Vertex Pharma has teamed up with Orum Therapeutics to develop a conditioning regimen, used to prepare patients to receive gene-editing medicines, that it hopes will offer a more tolerable alternative to current chemotherapy options.Vertex is paying $15 million upfront to get the ball rolling on the collaboration, which could be worth up to $945 million if it exercises options to use the technology for three developmental programmes and all of them hit various milestones.
Pharmaceutical Technology
JULY 17, 2024
The funds will finance late-stage trials of CRD-750, a PDE9 inhibitor for heart failure, and CRD-4730, a CaMKII inhibitor.
Drug Patent Watch
JULY 17, 2024
The High Stakes of Pharmaceutical Patent Litigation In the fiercely competitive pharmaceutical industry, patent disputes can make or break a […] Source
Pharmaceutical Technology
JULY 17, 2024
Scorpion Therapeutics has secured $150m in a Series C financing round to progress the development of its clinical-stage oncology pipeline.
Advertisement
This new white paper defines and details the impact of Decentralized Clinical Trials on the Pharmaceutical industry and how the impact can be measured along with steps companies can take to ensure adoption.
pharmaphorum
JULY 17, 2024
Huma raised $80m to support a cloud platform that can be used by digital health developers to create disease management tools
Pharmaceutical Technology
JULY 17, 2024
China’s NMPA has granted approval for Zai Lab and argenx's efgartigimod SC for the treatment of generalised myasthenia gravis (gMG).
Fierce Pharma
JULY 17, 2024
Bayer has claimed a second pivotal trial win for its blockbuster-to-be androgen receptor inhibitor Nubeqa, looking to reach the entire space of metastatic hormone-sensitive prostate cancer (mHSPC). | Bayer has claimed a second pivotal trial win for its blockbuster-to-be androgen receptor inhibitor Nubeqa, looking to reach the entire space of metastatic hormone-sensitive prostate cancer.
Pharma Times
JULY 17, 2024
The new technology can generate a target infection within 30 minutes to two hours
Advertisement
Planning on running clinical trials in Japan? How can you reliably supply these studies? Discover Catalent’s clinical supply packaging facility in Shiga, Japan. Strategically located between Tokyo and Osaka, and one of largest in Japan, this 6,000 square meter facility offers comprehensive services including primary and secondary clinical packaging and labelling, comparator sourcing, cold chain storage, local and global distribution, local language support and white glove service to support stud
Expert insights. Personalized for you.
246 
Let's personalize your content